B cells

[HUTCHMED Limited (Globe Newswire, Inc.)] HUTCHMED Limited announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation to HMPL-523, a novel, investigational spleen tyrosine kinase inhibitor, for the treatment of chronic adult primary immune thrombocytopenia patients who have received at least one prior therapy.

[Cancer Research] Investigators quantified tumor infiltration across two distinct clear cell renal cell carcinoma patient tumor cohorts using complementarity determining region-3 (CDR3) sequence recovery counts in tumor-infiltrating lymphocytes and a generalized diversity index for CDR3 sequence distributions.

[Molecular Therapy-Oncolytics] Investigators constructed a CAR targeting interleukin-13 receptor α2 according to a murine antibody, and then humanized the single-chain variable fragment sequence to generate another CAR.

[Science Immunology] Scientists described a population of CXCR5+ T follicular helper–like mucosal-associated invariant T (MAIT) cells that have the capacity to provide B cell help within mucosal lymphoid organs.

[Proceedings of the National Academy of Sciences of the United States of America] The authors demonstrated that lymph node CD169+ macrophages were dependent on direct lymphotoxin beta receptor signaling.

[Leukemia] When analyzing the effects of BH3-mimetics selectively targeting BCL-XL and MCL-1 alone or in combination with the BCL-2 inhibitor venetoclax, heterogeneous sensitivity to either of these inhibitors was found in ALL cell lines and in patient-derived xenografts.